Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease 56% of Patients with Low Tau Continued to Demonstrate ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, with lower rates of amyloid-related imaging abnormalities compared ...

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and ...

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid ...

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid ...

The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease.

What is dementia? While Alzheimer’s is a specific disease and the most common cause of dementia, dementia is a broader, "umbrella term that describes a collection of cognitive, functional and ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients new hope through MUSC's SCAN program ...

Home Health the explainer Why people can't access dementia 'wonder' drugs New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...